US · RLYB
Rallybio Corporation
- Sector
- Healthcare · Biotechnology
- Headquarters
- New Haven, CT 06510
- Website
- rallybio.com
Price · as of 2024-12-31
$9.41
Market cap 39.81M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | $79.68 | ||||
| 2022 | $42.16 | ||||
| 2023 | $14.96 | ||||
| 2024 | $5.95 |
AI valuation
Our deep-learning model estimates Rallybio Corporation's (RLYB) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $9.41
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| RLYB | Rallybio Corporation | $9.41 | 39.81M | — | — | — | — | -0.56 | 0.53 | 50.94 | 0.55 | — | 0.53 | 100.00% | -9511.95% | -9084.12% | -68.85% | 1714.74% | -62.89% | 0.00 | — | 10.87 | 10.50 | 0.23 | -2772.00% | — | -1824.00% | -152.12% | -7.90 | 1396.88% | 0.00% | 0.00% | 0.00% | 0.54 | 0.67 | -51.82 | -4.85 |
| BOLD | Boundless Bio, Inc. | $1.16 | 25.97M | — | — | — | — | -0.44 | 0.19 | — | 1.18 | -0.60 | 0.19 | 0.00% | — | — | -554.86% | 73.46% | -38.87% | 0.32 | — | 18.98 | 18.70 | -0.33 | 7342.00% | — | 3346.00% | -220.80% | -7.48 | 63.54% | 0.00% | 0.00% | 0.00% | 1.03 | 1.20 | — | -1.38 |
| CVKD | Cadrenal Therapeutics, In… | $8.49 | 19.85M | — | — | — | — | -1.93 | 2.76 | — | -0.99 | — | 2.76 | 0.00% | — | — | -140.78% | 670.96% | -114.27% | 0.00 | — | 3.77 | 3.75 | 0.94 | -935.00% | — | 10840.00% | -35.84% | -2.74 | 450.80% | 0.00% | 0.00% | 7.97% | -0.96 | -1.43 | — | -1.66 |
| IBIO | iBio, Inc. | $2.82 | 44.53M | +1,048% | -88% | — | — | -0.48 | 0.59 | 22.05 | -0.22 | — | 1.10 | 100.00% | -4650.50% | -4594.25% | -101.52% | -174.01% | -70.79% | 0.24 | -87.75 | 1.59 | 1.42 | 0.30 | -7308.00% | 7778.00% | -1835.00% | -173.71% | -2.51 | -143.31% | 0.00% | 0.00% | 0.00% | -0.20 | -0.24 | 9.36 | -21.87 |
| INTS | Intensity Therapeutics, I… | $7.66 | 14.45M | — | — | — | — | -1.89 | 10.53 | — | -1.74 | — | 10.53 | 0.00% | — | — | -202.34% | 3350.51% | -147.37% | 0.05 | — | 1.92 | 1.48 | 0.15 | -1522.00% | — | 11124.00% | -49.52% | -8.67 | 3074.75% | 0.00% | 0.00% | 0.00% | -1.71 | -1.86 | — | -20.70 |
| ITRM | Iterum Therapeutics plc | $0.26 | 13.97M | — | — | — | — | -1.10 | -6.66 | — | -2.24 | — | -1.14 | 0.00% | — | — | 472.61% | -628.33% | -69.93% | -11.16 | — | 1.41 | 1.37 | -0.99 | -5743.00% | — | -3195.00% | -98.48% | -1.52 | -899.75% | 0.00% | 0.00% | 0.00% | -2.60 | -1.82 | — | -16.11 |
| KLTO | Klotho Neurosciences, Inc… | $0.53 | 28.02M | — | — | — | — | -0.90 | 4.69 | — | -1.00 | 0.00 | -4.99 | 0.00% | — | — | -700.07% | -323.09% | -264.53% | 0.23 | -15.54 | 0.13 | 0.05 | -0.04 | 4561429.00% | — | 56623.00% | -55.19% | -2.36 | -179.03% | 0.00% | 0.00% | 24.75% | -1.04 | -1.88 | — | -11.37 |
| QTTB | Q32 Bio Inc. | $4.56 | 56.11M | +726% | — | — | — | -0.57 | 4.77 | — | 0.71 | — | 4.77 | 0.00% | — | — | 53.86% | 62.63% | -68.49% | 3.33 | -220.34 | 4.97 | 4.77 | 1.30 | -6060.00% | -10000.00% | 26286.00% | -250.34% | -4.11 | 64.23% | 0.00% | 0.00% | 311.27% | 0.48 | 0.47 | — | -4.89 |
| SONN | Sonnet BioTherapeutics Ho… | $1.26 | 8.43M | +87,488% | -33% | — | +67,885% | -0.19 | -2.83 | 73.88 | -0.12 | — | -2.83 | 100.00% | -63617.91% | -39929.30% | 2089.93% | 846.19% | -181.38% | -0.27 | — | 0.66 | 0.28 | 0.00 | -9218.00% | -8740.00% | -6049.00% | -625.56% | -2.68 | 614.69% | 0.00% | 0.00% | 0.00% | -0.11 | -0.16 | 72.88 | -73.78 |
| TAOX | TAO Synergies Inc. | $3.91 | 13.63M | — | — | — | — | — | — | — | — | — | — | 0.00% | — | — | -78.91% | 0.00% | -52.28% | 0.00 | — | 17.47 | 17.41 | 2.59 | -10000.00% | — | -564.00% | — | -4.82 | 63.45% | — | -7.40% | — | — | — | — | — |
| XCUR | Exicure, Inc. | $3.74 | 23.84M | — | +24% | — | — | -7.29 | 10.45 | 141.51 | -7.25 | — | 10.45 | 100.00% | -2446.40% | -1940.20% | -197.92% | -269.46% | -72.84% | 0.88 | -679.56 | 4.45 | 4.24 | 0.74 | -2464.00% | — | -7190.00% | -4.11% | -0.95 | -64.10% | 0.00% | 0.00% | 17.56% | -5.25 | -22.06 | 128.36 | -15.21 |
About Rallybio Corporation
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody which is in Phase II clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.
- CEO
- Stephen Uden
- Employees
- 15
- Beta
- -1.05
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $9.41) − 1 = — (DCF, example).